Markets & Industry
Psychedelics investment fund raises $50m to accelerate therapies
Palo Santo says the oversubscribed fund is positioned to have a transformative impact on the field of mental health.

Published
1 year agoon

Palo Santo has announced the closing of its USD$50m (~£134.10m) fund which will go towards a diverse portfolio of businesses developing innovative psychedelic medicines and therapies.
The funded therapies will be targeting mental health and a range of central nervous system disorders.
To date, the fund is over 20 portfolio companies across the psychedelic ecosystem, including Beckley Psytech, Tactogen, Bexson Biomedical, Ksana Health, Gilgamesh Pharmaceuticals, Delix Therapeutics, Journey Clinical and Fluence, among others.
The company states that it combines its investing and portfolio-building experience with the expertise of leading academics and advisors in psychedelic science.
Palo Santo co-founder, Tim Schlidt, commented: “Following decades of criminalization, psychedelics are demonstrating their potential to treat mental health disorders more rapidly and durably than currently available treatments, in a field that hasn’t seen substantial innovation for over 30 years.
“Against the backdrop of a growing global mental health crisis, our mission is to drive clinical development and FDA approval of these much-needed therapies that we believe will become the future standard of care.
“We are proud to play a role in this paradigm shift and look forward to creating value for our portfolio companies, investors, and most importantly patients and their loved ones.”
Co-founder Daniel Goldberg added: “It’s very encouraging to see the momentum in psychedelic drug development supported by leading academic institutions, investors, regulators and politicians from both sides of the aisle.
“MDMA is expected to be approved within the next two years as a breakthrough therapy for treatment of PTSD and psilocybin approximately two years after that for depression.
“With roughly fifty percent of our Fund still to deploy, we are well positioned to put money to work in a more favourable investing environment while fostering innovation in the mental health field.”
Palo Santo’s advisory board includes pharmacology expertise with leading serotonin 2A researchers Charles D. Nichols, PhD and John D. McCorvy, PhD; psychiatric expertise with Julie Holland, MD and John F. Greden, MD; clinical and commercial expertise with Stephen Wright, MD; intellectual property know-how with Gretchen Temeles, PhD, J.D.; and aptitude around medicinal chemistry with David Sherman, PhD.
Beckley Psytech CEO, Cosmo Feilding Mellen, commented: “Globally, there is a huge unmet patient need for more effective mental health treatments. Psychedelic therapies represent a potentially exciting new class of neuropsychiatric treatments and it’s been so important for this nascent industry to have the backing of diligent investors such as Palo Santo.
“We are grateful for their support, which has helped us to advance our pipeline of psychedelic programs, and look forward to continuing to work with their team.”
Palo Santo Scientific Advisor and Medical Advisor to the Multidisciplinary Association for Psychedelic Studies (MAPS) Julie Holland, MD, concluded: “Having been a clinical psychiatrist and psychopharmacologist for the past 25 years, I see incredible potential for psychedelics to benefit patients, including those whose therapies are no longer effective.
“It’s crucial that the most promising companies and therapies receive the funding needed to advance psychedelic medicines through clinical trials in a timely manner, and I am proud to be part of a team of experts who share that same goal.”
You may like
Ketamine: understanding the K-Hole
Mychedelica launches to revolutionise psychedelic medicine
Clearmind Medicine announces receipt of Nasdaq delisting notice
Paper explores extended difficulties following psychedelic trips
Transform Drugs releases groundbreaking book: How to regulate psychedelics
PAREA’s psychedelic push: improving policy for mental health innovation in Europe
Markets & Industry
Psychedelic therapy programmes launch to address heartbreak, burnout and more

Published
3 days agoon
1st December 2023By
News Editor
Mindbloom has launched its new Mastermind Series of psychedelic programmes for overcoming heartbreak, burnout and other unique mental health challenges.
Led by and developed with leading experts in the field, each programme combines specialised teachings with ketamine therapy.
All programmes will include six ketamine therapy sessions focusing on a specific mental health issue, expert-led audio, video, and written content for preparation, treatment, and integration, practical tools such as meditation, one-on-one coaching and group integration sessions.
The first programme in the Series is ‘Recovering from Rejection and Failure’, led by Dr Guy Winch who is a leading authority on emotional health, and a best-selling author and TED speaker whose talks have received over 30 million views.
Winch’s programme focuses on healing and preventing emotional injuries that people suffer in their personal, professional and romantic lives.
Mindbloom CEO and Founder Dylan Beynon stated: “More than 100 studies and 20 plus years of clinical use show that ketamine therapy may be the most transformational mental health treatment available today.
“In the face of epidemics of mental illness, addiction, and loneliness, we’re thrilled to offer our clients access to top experts across a range of issues – and to pair their expertise with our best-in-class ketamine therapy honed over hundreds of thousands of treatment sessions.”
“Emotional wounds like rejection and failure can be even more devastating than physical wounds, yet we don’t give them the same time and attention,” added Dr Winch.
“I’m thrilled to combine my techniques for emotional first aid with ketamine therapy, which has been shown to increase neuroplasticity and help build emotional resilience.”
Additional Mastermind
“Americans are struggling with heartbreak, burnout, and other challenges every day, and they’re looking for new tools to address them,” said Mindbloom’s Medical Director Dr Leonardo Vando.
“I’m grateful to these experts for providing Mindbloom’s clients with the unique practices and insights they’ve cultivated during their distinguished careers, to help them overcome the biggest obstacles in their lives.”
Markets & Industry
Mychedelica launches to revolutionise psychedelic medicine

Published
6 days agoon
28th November 2023By
News Editor
A new company specialising in psychedelic medicine – mychedelica – is offering a comprehensive suite of services to support the advancement of this transformative field.
With a team of experienced medical writers and research support specialists, mychedelica is committed to providing the highest quality services to researchers, clinicians, and pharmaceutical companies working in the psychedelic medicine space.
Psychedelic medicine is rapidly gaining recognition for its potential to treat a wide range of mental health conditions, including depression, anxiety, addiction, and post-traumatic stress disorder (PTSD). However, the field is still in its early stages of development, and there is a critical need for high-quality medical writing and research support services to facilitate its progress.
CEO of mychedelica, Bilal Bham, commented: “We are thrilled to launch mychedelica and contribute to the advancement of psychedelic medicine.
“Our team of experienced professionals is dedicated to providing the highest quality services to researchers, clinicians, and pharmaceutical companies working in this groundbreaking field.”
mychedelica provides a comprehensive range of services, including:
Medical writing: Experienced medical writers will craft clinical trial protocols, regulatory submissions, and peer-reviewed publications, ensuring that research findings are communicated clearly and effectively.
Funding research support: Experts in grant writing and fundraising strategies will assist researchers in securing funding for their psychedelic medicine studies.
Regulatory consulting: mychedelica’s team of regulatory experts will navigate the complex regulatory landscape surrounding psychedelic medicine, ensuring that clinical trials and products comply with all applicable laws and regulations.
With its commitment to quality and innovation, mychedelica is poised to play a pivotal role in shaping the future of psychedelic medicine. The company’s services will empower researchers to conduct rigorous clinical trials, clinicians to provide effective treatments, and pharmaceutical companies to develop safe and effective psychedelic medicines.
Markets & Industry
Short Wave Pharma: innovating eating disorder care with psychedelics

Published
2 weeks agoon
24th November 2023
Psychedelic Health speaks to Short Wave Pharma CEO Rivki Stern about the company’s plans to innovate eating disorder care through psychedelics and its recent acquisition by Psych Capital.
Short Wave Pharma was recently acquired by global investment firm Psych Capital. The companies are on a mission to transform mental health care, focusing on innovative approaches and treatments, including psychedelics, which are increasingly gaining acceptability as clinical research results accumulate.
Short Wave Pharma’s clinical programmes are particularly focused on Anorexia nervosa – a complex mental health condition with one of the highest fatality rates. Despite the condition being associated with high rates of suicide, it is a hugely underserved area of mental health, with no FDA-approved pharmacological drug, and a high rate of chronicity.
The company has developed a novel delivery method and drug combination specifically designed to address the requirements of this vulnerable population. Short Wave focuses on methods of delivery that will be effective for Anorexia, which is a metabolic disease as well as a mental health condition. Its unique buccal film delivery method is intended to affect the brain while bypassing the liver and gut degradation through mucoadhesive absorption.
“Our goal is to alleviate, solve, and treat mental health conditions. It’s a dire need in our global society, and it’s constantly on the rise,” commented Stern. “Eating disorders are a very good example of that and we have seen a very alarming growth since COVID.
“What drew our attention to psychedelics is that they have the potential to address very complex mental health diseases and have been designated by FDA as breakthrough medicine for life-threatening conditions.
“Because there are no current solutions, we must harness very innovative approaches and potential solutions. That’s why we started working with psychedelics which may be difficult because they are not regulated, but we don’t shy away from challenges.”
The company’s drug is based on psilocybin and another API which together utilise an expanded mechanism of action and a therapeutic effect superior to psilocybin alone, impacting more than one group of receptors in the brain.
The delivery method is sensitive to the patients’ needs – who may not want to swallow or be injected – and is known for its high bioavailability.
“By mucosal absorption, we are speeding the onset of the medicine and amplifying the impact which will help tackle the patients’ metabolic challenges and improve acceptance,” says Stern.
The drug product and delivery method are currently in preparation for Phase 1 clinical studies, and in its current preclinical studies, the company is validating its delivery and expanded mechanisms of action. So far, initial safety results are positive, with a further, more in-depth toxicity study taking place.
Psych Capital – which is a public investment and awareness platform for mental health, and has a portfolio of innovative companies – has supported Short Wave Pharma’s IP-driven approach to eating disorder care through its recent acquisition of the company.
Short Wave and Psych Capital say they are aligned in their missions to innovate mental healthcare and deliver transformative care in areas of high unmet need.
Stern commented: “We all share a passion for innovation and together have decades of experience in evaluating investments as well as scaling up R&D projects and start-ups in life sciences.
“We have a shared commitment to alleviate the suffering from mental health. Every one of us has experienced the frustration and challenges of dealing with mental health issues.
“Together, we’re going to put this commitment into action, by bringing forth innovative solutions and developments and getting them through the first stages of development, from discovery through to early phases of clinical study.
“With psychedelics components, this is extra challenging because of their status as scheduled drugs within a still evolving regulatory framework, which adds uncertainty to the drug development process.
“Short Wave Pharma has operational expertise in early-stage drug development which will bring extra value to the group’s projects as they develop through our funnel and grow into promising candidates for mental healthcare.
“We want to identify the gems, guide them through clinical development, and create the right network to attract the right partners for further development and commercialisation.”
Short Wave Pharma is planning to enter its treatment into clinical studies in 2024.
Recent Articles
- Psychedelic therapy programmes launch to address heartbreak, burnout and more
- Psilocybin analogue shows positive results in Phase 2 depression study
- Ketamine: understanding the K-Hole
- Mychedelica launches to revolutionise psychedelic medicine
- Clerkenwell Health calls for volunteers to support groundbreaking psychedelic research
- Short Wave Pharma: innovating eating disorder care with psychedelics
Trending
- Psychedelic therapy programmes launch to address heartbreak, burnout and more
- Psilocybin analogue shows positive results in Phase 2 depression study
- Ketamine: understanding the K-Hole
- Mychedelica launches to revolutionise psychedelic medicine
- Clerkenwell Health calls for volunteers to support groundbreaking psychedelic research
Trending
- Opinion2 years ago
Clerkenwell Health is launching a free UK psychedelic therapist training programme
- Insight2 years ago
Mixing psychedelics with lithium poses significant risk of seizures
- Medicinal2 years ago
MDMA therapy for PTSD granted innovation passport by UK
- Research2 years ago
LSD trial for the treatment of adult ADHD initiated
- Markets & Industry12 months ago
Where can I find training for psychedelic therapy?
- Medicinal2 years ago
MDMA: the love drug?
- News2 years ago
Awakn’s second psychedelic therapy clinic to open in London
- Research2 years ago
London to host Europe’s first commercial psychedelic clinical trial facility